Genelux Statistics
Total Valuation
Genelux has a market cap or net worth of $122.34 million. The enterprise value is $106.09 million.
| Market Cap | 122.34M |
| Enterprise Value | 106.09M |
Important Dates
The last earnings date was Thursday, August 13, 2026.
| Earnings Date | Aug 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Genelux has 44.81 million shares outstanding. The number of shares has increased by 16.39% in one year.
| Current Share Class | 44.81M |
| Shares Outstanding | 44.81M |
| Shares Change (YoY) | +16.39% |
| Shares Change (QoQ) | +1.83% |
| Owned by Insiders (%) | 9.07% |
| Owned by Institutions (%) | 21.92% |
| Float | 36.52M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 15,292.10 |
| Forward PS | n/a |
| PB Ratio | 7.57 |
| P/TBV Ratio | 7.59 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 13,260.85 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.39, with a Debt / Equity ratio of 0.15.
| Current Ratio | 2.39 |
| Quick Ratio | 2.33 |
| Debt / Equity | 0.15 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -177.93% and return on invested capital (ROIC) is -103.15%.
| Return on Equity (ROE) | -177.93% |
| Return on Assets (ROA) | -77.89% |
| Return on Invested Capital (ROIC) | -103.15% |
| Return on Capital Employed (ROCE) | -200.04% |
| Weighted Average Cost of Capital (WACC) | 7.34% |
| Revenue Per Employee | $308 |
| Profits Per Employee | -$1.37M |
| Employee Count | 26 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -27.01% in the last 52 weeks. The beta is 0.59, so Genelux's price volatility has been lower than the market average.
| Beta (5Y) | 0.59 |
| 52-Week Price Change | -27.01% |
| 50-Day Moving Average | 2.85 |
| 200-Day Moving Average | 3.16 |
| Relative Strength Index (RSI) | 47.96 |
| Average Volume (20 Days) | 362,647 |
Short Selling Information
The latest short interest is 3.52 million, so 7.85% of the outstanding shares have been sold short.
| Short Interest | 3.52M |
| Short Previous Month | 3.08M |
| Short % of Shares Out | 7.85% |
| Short % of Float | 9.63% |
| Short Ratio (days to cover) | 13.23 |
Income Statement
In the last 12 months, Genelux had revenue of $8,000 and -$35.60 million in losses. Loss per share was -$0.86.
| Revenue | 8,000 |
| Gross Profit | 8,000 |
| Operating Income | -36.42M |
| Pretax Income | -35.60M |
| Net Income | -35.60M |
| EBITDA | -36.28M |
| EBIT | -36.42M |
| Loss Per Share | -$0.86 |
Balance Sheet
The company has $18.67 million in cash and $2.42 million in debt, with a net cash position of $16.25 million or $0.36 per share.
| Cash & Cash Equivalents | 18.67M |
| Total Debt | 2.42M |
| Net Cash | 16.25M |
| Net Cash Per Share | $0.36 |
| Equity (Book Value) | 16.11M |
| Book Value Per Share | 0.36 |
| Working Capital | 11.15M |
Cash Flow
In the last 12 months, operating cash flow was -$25.28 million and capital expenditures -$3.41 million, giving a free cash flow of -$28.68 million.
| Operating Cash Flow | -25.28M |
| Capital Expenditures | -3.41M |
| Depreciation & Amortization | 142,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -28.68M |
| FCF Per Share | -$0.64 |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -455,275.00% |
| Pretax Margin | -444,950.00% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Genelux does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -16.39% |
| Shareholder Yield | -16.39% |
| Earnings Yield | -29.10% |
| FCF Yield | -23.45% |
Analyst Forecast
The average price target for Genelux is $17.50, which is 541.03% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $17.50 |
| Price Target Difference | 541.03% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | 1,962.27% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Genelux has an Altman Z-Score of -11.56 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -11.56 |
| Piotroski F-Score | 1 |